Clearmind Medicine (CMND) Income towards Parent Company (2022 - 2026)
Clearmind Medicine (CMND) posted quarterly Income towards Parent Company of -$2.0 million for Q2 2026, down 174.84% year-over-year from $2.7 million in Q2 2025, and up 46.94% quarter-over-quarter from -$3.8 million in Q1 2026.
Clearmind Medicine (CMND) Income towards Parent Company (2022 - 2026) Analysis & Trends
Clearmind Medicine's Income towards Parent Company history runs 5 years deep, the most recent figure standing at -$2.0 million for Q2 2026.
- In Q2 2026, Income towards Parent Company fell 174.84% year-over-year to -$2.0 million; the TTM figure through Apr 2026 stood at -$8.1 million (down 45.09% YoY), while the FY2025 annual figure was -$3.9 million, up 30.27% from the prior year.
- Income towards Parent Company for Q2 2026 stood at -$2.0 million, up from -$3.8 million in the prior quarter.
- The five-year high for Income towards Parent Company was -$588449.0 in Q3 2023, with the low at -$4.1 million in Q4 2023.
- The 5-year median for Income towards Parent Company is -$1.5 million (2023), against an average of -$1.7 million.
- The sharpest annual moves came in 2023 and 2026: Income towards Parent Company surged 60.32% in 2023, then sank 287.4% in 2026.
- Clearmind Medicine's Income towards Parent Company stood at -$1.5 million in 2022, then slumped by 176.41% to -$4.1 million in 2023, then surged by 55.49% to -$1.8 million in 2024, then jumped by 50.95% to -$894789.0 in 2025, then sank by 128.1% to -$2.0 million in 2026.
- Business Quant data shows CMND's Income towards Parent Company at -$2.0 million in Q2 2026, -$3.8 million in Q1 2026, and -$894789.0 in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Clearmind Medicine | 537,435.54 | -13.06 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Apr 30, 2026 | -2.04 Mn |
| Jan 31, 2026 | -3.85 Mn |
| Oct 31, 2025 | -894,789.00 |
| Jul 31, 2025 | -1.30 Mn |
| Apr 30, 2025 | -742,612.00 |
| Jan 31, 2025 | -992,951.00 |
| Oct 31, 2024 | -1.82 Mn |
| Jul 31, 2024 | -2.01 Mn |
| Apr 30, 2024 | -834,705.00 |
| Jan 31, 2024 | -964,800.00 |
| Oct 31, 2023 | -4.10 Mn |
| Jul 31, 2023 | -588,449.00 |
| Apr 30, 2023 | -1.52 Mn |
| Jan 31, 2023 | -1.82 Mn |
| Jul 31, 2022 | -1.48 Mn |
| Apr 30, 2022 | -1.84 Mn |
| Jan 31, 2022 | -1.65 Mn |